Arbutus Biopharma
ABUSABUS · Stock Price
Historical price data
Overview
Arbutus Biopharma is a pure-play virology company with a mission to achieve a functional cure for chronic hepatitis B (HBV). Its core strategy is a multi-mechanistic combination approach, anchored by its RNAi therapeutic imdusiran, which has demonstrated meaningful functional cure rates in clinical trials. The company is led by a newly appointed, transaction-savvy leadership team with deep expertise in building and scaling biotech ventures. Arbutus's concentrated focus on the large, underserved HBV market positions it as a key contender in the race for a curative regimen.
Technology Platform
A proprietary three-pillar combination therapy framework ('Suppress, Reduce, Boost') for HBV, integrating RNAi for antigen reduction with immune modulation and standard antivirals.
Pipeline
12| Drug | Indication | Stage | Watch |
|---|---|---|---|
| VBR + AB-729 + SOC NrtI | Chronic Hepatitis B | Phase 2 | |
| Imdusiran (AB-729) | Chronic Hepatitis B | Phase 2 | |
| Imdusiran + Durvalumab | Hepatitis B, Chronic | Phase 2 | |
| ARB-001467 | Hepatitis B, Chronic | Phase 2 | |
| AB-729 + Peg-IFNα-2a | Chronic Hepatitis b | Phase 2 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
The HBV cure landscape is competitive, with major players like Gilead, Janssen/Arrowhead, and GSK advancing combination therapies. Arbutus differentiates through its dedicated focus on a multi-mechanistic 'Suppress, Reduce, Boost' paradigm and a leadership team with strong transactional expertise to navigate partnerships.